KRAS and lung carcinoma: Consistent with the previous results with IEC6 rat intestinal epithelial cells and colorectal and lung cancer cells (Fujii et al., 2015; Matsumoto et al., 2014), the MEK inhibitors PD184161 and U0126 and siRNAs for β-catenin and KRAS decreased ARL4C expression in S2-CP8 and PANC-1 cells (Figure 1F–H).